DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL 10 MG
DOXORUBICIN HYDROCHLORIDE : 10 MG · DIN 02093057 · DAVID BULL LABORATORIES (PTY) LTD.
Health Canada status: CANCELLED POST MARKET
What is DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL?
DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL 10 MG contains DOXORUBICIN HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02093057, held by DAVID BULL LABORATORIES (PTY) LTD., supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 13-Aug-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL called?
The same molecule, DOXORUBICIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Adriamycin | Latin | Australia |
| Doxorubicin ACC | Latin | Australia |
| Doxorubicin Pch | Latin | South Africa |
| Doxorubicin Rtu | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02093057 |
|---|---|
| Brand name | DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL |
| Generic / active ingredient | DOXORUBICIN HYDROCHLORIDE : 10 MG |
| Manufacturer | DAVID BULL LABORATORIES (PTY) LTD. |
| Strength | 10 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01DB01 DOXORUBICIN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 13-Aug-1998 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02093057 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2093057 |
| Brand name | DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL |
| Active ingredient / INN | DOXORUBICIN HYDROCHLORIDE : 10 MG |
| ATC code | L01DB01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01 |
| AHFS class | 10:00.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | DAVID BULL LABORATORIES (PTY) LTD. |
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is DOXORUBICIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by TEVA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL
What can be used instead?
Other Canadian products sharing ATC code L01DB01 DOXORUBICIN. 7 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAELYX | 2 MG | SUSPENSION | BAXTER CORPORATION | MARKETED | DIN 02238389 |
| DOXORUBICIN | 2 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02410397 |
| DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | 150 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02194473 |
| DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | 50 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02194465 |
| DOXORUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02409275 |
| DOXORUBICIN INJECTION, BP | 2 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02381982 |
| TARO-DOXORUBICIN LIPOSOMAL | 2 MG | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02493020 |
| ADRIAMYCIN PFS | 2 MG | SOLUTION | PFIZER CANADA ULC | DORMANT | DIN 02071002 |
| ADRIAMYCIN RDF | 10 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02065657 |
| ADRIAMYCIN RDF | 150 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02069563 |
Who else supplies DOXORUBICIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOXORUBICIN appears in 108 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does DOXORUBICIN cost around the world?
DOXORUBICIN is listed on 6 national price registers Nexara tracks, across 56 pack listings published on 5 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 19 | 19 | 01 Sep 2026 |
| Romania | max producer price | 5 | 11 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 10 | 10 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 4 | 9 | 03 Sep 2026 |
| Australia | ex-manufacturer | 2 | 4 | 08 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.